BR112023001307A2 - Combinação de inibidor de bcl-2 e agente hipometilante para tratamento de câncer, usos e composições farmacêuticas dos mesmos - Google Patents

Combinação de inibidor de bcl-2 e agente hipometilante para tratamento de câncer, usos e composições farmacêuticas dos mesmos

Info

Publication number
BR112023001307A2
BR112023001307A2 BR112023001307A BR112023001307A BR112023001307A2 BR 112023001307 A2 BR112023001307 A2 BR 112023001307A2 BR 112023001307 A BR112023001307 A BR 112023001307A BR 112023001307 A BR112023001307 A BR 112023001307A BR 112023001307 A2 BR112023001307 A2 BR 112023001307A2
Authority
BR
Brazil
Prior art keywords
bcl
inhibitor
agent
combination
pharmaceutical compositions
Prior art date
Application number
BR112023001307A
Other languages
English (en)
Portuguese (pt)
Inventor
Dessein Emmelyne
Mahnke Lisa
Robert Cooper Michael
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of BR112023001307A2 publication Critical patent/BR112023001307A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112023001307A 2020-07-31 2021-07-30 Combinação de inibidor de bcl-2 e agente hipometilante para tratamento de câncer, usos e composições farmacêuticas dos mesmos BR112023001307A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059419P 2020-07-31 2020-07-31
EP20195633 2020-09-11
PCT/EP2021/071368 WO2022023514A1 (en) 2020-07-31 2021-07-30 Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
BR112023001307A2 true BR112023001307A2 (pt) 2023-02-14

Family

ID=77595496

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001307A BR112023001307A2 (pt) 2020-07-31 2021-07-30 Combinação de inibidor de bcl-2 e agente hipometilante para tratamento de câncer, usos e composições farmacêuticas dos mesmos

Country Status (15)

Country Link
US (1) US20230270748A1 (https=)
EP (1) EP4188387A1 (https=)
JP (1) JP2023537290A (https=)
KR (1) KR20230044452A (https=)
CN (1) CN116390735A (https=)
AU (1) AU2021316674A1 (https=)
BR (1) BR112023001307A2 (https=)
CA (1) CA3190276A1 (https=)
CL (1) CL2023000242A1 (https=)
CR (1) CR20230046A (https=)
IL (1) IL300145A (https=)
JO (1) JOP20230013A1 (https=)
MX (1) MX2023001335A (https=)
PH (1) PH12023550205A1 (https=)
WO (1) WO2022023514A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025252168A1 (zh) * 2024-06-06 2025-12-11 苏州亚盛药业有限公司 一种含有Bcl-2/Bcl-xL抑制剂的药物组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2017300738A1 (en) * 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
UY38431A (es) 2018-10-31 2020-05-29 Servier Lab Formulación basada en ciclodextrina de un inhibidor de bcl-2
SI3873894T1 (sl) 2018-10-31 2023-08-31 Les Laboratoires Servier Nova sol Bcl-2 inhibitorja, z njo povezana kristalna oblika, postopek za pripravo le-teh in farmacevtski sestavki, ki jih vsebujejo

Also Published As

Publication number Publication date
CA3190276A1 (en) 2022-02-03
KR20230044452A (ko) 2023-04-04
CN116390735A (zh) 2023-07-04
CR20230046A (es) 2023-04-11
WO2022023514A1 (en) 2022-02-03
IL300145A (en) 2023-03-01
MX2023001335A (es) 2023-04-27
US20230270748A1 (en) 2023-08-31
CL2023000242A1 (es) 2023-11-10
PH12023550205A1 (en) 2024-06-24
EP4188387A1 (en) 2023-06-07
JP2023537290A (ja) 2023-08-31
JOP20230013A1 (ar) 2023-01-18
AU2021316674A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
Mamdani et al. Histone deacetylase inhibition in non-small cell lung cancer: hype or hope?
Chu et al. Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer
Chen et al. Nanoparticle-based drug delivery systems for targeted epigenetics cancer therapy
Mohamed et al. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia
Becker et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2
Sivaraj et al. Panobinostat for the management of multiple myeloma
Miller et al. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors
Daenen et al. Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies
Fiskus et al. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells
Cao et al. Chidamide combined with doxorubicin induced p53-driven cell cycle arrest and cell apoptosis reverse multidrug resistance of breast cancer
Li et al. DNA methyltransferase-1 in acute myeloid leukaemia: beyond the maintenance of DNA methylation
BR112023001307A2 (pt) Combinação de inibidor de bcl-2 e agente hipometilante para tratamento de câncer, usos e composições farmacêuticas dos mesmos
Altucci et al. Epigenetic therapies in haematological malignancies: searching for true targets
Sebova et al. Epigenetic tools in potential anticancer therapy
De Schutter et al. Radiosensitizing potential of epigenetic anticancer drugs
Benjamin et al. All-trans-retinoic acid combined with valproic acid can promote differentiation in myeloid leukemia cells by an autophagy dependent mechanism
NI202100031A (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
Ahmad Ganai et al. Plant derived inhibitor Sulforaphane in combinatorial therapy against therapeutically challenging Pancreatic Cancer
Liu et al. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis
Tang et al. Epigenetic mechanisms of drug resistance in acute myeloid leukemia: advances in small-molecule targeted therapy
Oratz et al. Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma
Lun et al. Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.
Sweeney Why cyclooxygenase-2 inhibition plus chemotherapy?
WO2021247714A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and hormone therapy agent
Jafary et al. Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells